Company: BNBX
Filing Date: 2025-12-30
Form Type: 424B3
Source: 0001104659-25-125037
Chunk: 18

Company: BNB PLUS CORP.
Filing Date: 2025-12-30
Form: 424B3
Chunk 18
---
 and RNA, which are essential components for a new
generation of advanced biotherapeutics such as gene therapies, personalized medicine, adoptive cell therapies and messenger RNA (“mRNA”)
and DNA-based vaccines, as well as in vitro diagnostic (“IVD”) applications.

<div align='center'>7</div>

The Company has developed three distinct and complementary technology solutions:

| · | LineaDNA™:                                                                                       
 A proprietary, cell-free DNA production system that uses a large-scale polymerase chain reaction 
 (“PCR”) process. This technology allows for the rapid and efficient production                   
 of high-fidelity synthetic DNA without the use of living cells. The resulting DNA can be         
 used in the manufacturing of various biotherapeutics, serve as the starting material for         
 mRNA therapeutics and vaccines, and as a critical component of IVDs.                             |

| · | LineaRNAP™:                                                                                  
 A next-generation RNA polymerase (“RNAP”) used to transform DNA into mRNA. Our               
 RNAP is engineered with a patented DNA-binding domain that we believe results in high mRNA   
 yields and reduced double-stranded RNA (dsDNA) contamination, a common problematic byproduct 
 produced during mRNA production.                                                             |

| · | LineaIVT™:                                                                                  
 An integrated system that combines the Company’s LineaDNA and LineaRNAP technologies.       
 This innovative solution simplifies the mRNA production workflow resulting in a streamlined 
 production process with fewer impurities than traditional methods.                          |

Our business strategy is to continue advancing our nucleic acid production solutions to support potential future sales and/or licensing agreements of our LineaRx business and/or its technology solutions with third-party partners. LineaDNA LineaDNA is our core enabling technology for rapid, efficient, and scalable cell-free manufacture of high-fidelity synthetic DNA sequences used in the manufacturing of a broad range of biotherapeutics. The LineaDNA platform enzymatically produces a linear form of synthetic DNA we call “LineaDNA” that is an alternative to plasmid-based DNA manufacturing technologies that have supplied the DNA used in biotherapeutics for the past 40 years. LineaDNA can be quickly produced in batches ranging from milligram to grams under a variety of controlled manufacturing processes including research use only (“RUO”), good laboratory practices (“GLP”) and good manufacturing practices (“GMP”). We believe LineaDNA holds several important advantages over existing cell-based plasmid DNA manufacturing platforms. Plasmid-based DNA manufacturing is based on the complex, costly and time-consuming biological